ERBB2 and neoplasm: A recent study also showed that in addition to direct anti-tumour effects, the anti-HER2 targeting ADC was able to enhance anti-tumour immune responses through the activation of antigen-presenting cells and also increasing MHC class I expression on tumour cells52.